Portfolio

Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients

December 9, 2024

Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute and Brenden-Colson Center for Pancreatic Care (BCCPC). This trial will evaluate the pharmacodynamic effects of OMO-103 in patients with pancreatic ductal adenocarcinoma (PDAC). The study aims to expedite drug development, improve understanding of pharmacodynamic parameters, and identify biomarkers for better patient selection.

 

Read more